Registry study evaluates polypharmacy and drug-drug interactions in people with four-class-resistant HIV, highlighting therapy complexity.
To evaluate polypharmacy, anticholinergic burden (ACB) and drug-drug interactions (DDIs) in people with four-class-resistant HIV (4DR-PWH).
No takes yet. Share an insight, caveat, or question.
Mazzitelli et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: